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Abstract
Objectives
To assess the effect of treatment with ivermectin on the prevalence of S. stercoralis infection
in an Australian Aboriginal population over a three year period, and to assess the validity of
using a lower ELISA cut-off in diagnosis.
Methods
A three-year cohort study of 259 adult Australian Aboriginals living in a remote community in
northern Australia. S stercoralis infection was diagnosed using commercial ELISA testing,
and employed a lower threshold for treatment than that recommended. Follow up was con-
ducted at 6 months and 3 years following ivermectin treatment.
Findings
Treatment with ivermectin was highly effective and resulted in a sustained fall in the preva-
lence of infection in the study group (Initial prevalence 35.3%, 3 year prevalence 5.8%,
McNemar’s chi2 = 56.5, p<0.001). Results of treatment suggested use of a lower ELISA
threshold for treatment was valid in this setting. Follow up identified a small group of subjects
with persistently positive ELISA serology despite repeated treatment.
Interpretation
Control of S. stercoralis infection in this cohort appears to be feasible using pharmacological
treatment alone.
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Author summary
Infection with the worm Strongyloides stercoralis is common throughout the developing
world, and in some resource poor communities living within developed societies, such as
the Aboriginal communities of northern Australia. It is generally agreed that reliable diag-
nosis of this infection is possible by blood tests, and that the medication ivermectin repre-
sents the best available treatment, however questions remain over how to best control and
eliminate the infection in areas where it is common. Strongyloides infections may be
asymptomatic, and may persist indefinitely without the need for re-infection. The worm
is transmitted by contact with contaminated soil. Suggested strategies for control have
therefore included mass administration of ivermectin in affected areas, and environmen-
tal measures to prevent the contamination of soil. In this study we follow up a group of
subjects living in an endemic community three years after they were tested and treated for
strongyloides infection. We find a persisting low prevalence of infection in this group in
the absence of any environmental changes or further treatment, suggesting that control of
the infection in this community might be achieved through simple case finding and treat-
ment alone. In addition, we suggest the use of a lower cut-off value for serological testing
in these communities, in order to avoid missing cases of infection.
Introduction
Infection with the soil-transmitted helminth (STH) Strongyloides stercoralis is common in
both the developing world, and in underprivileged communities in developed countries. Prev-
alence is frequently estimated at 30–100 million cases world wide, but due to difficulties with
diagnosis, the frequent absence of symptoms in chronic cases, and the lack of extensive screen-
ing for the infection, this may be an under-estimate [1]. The major medical impact of infection
is thought to be the occurrence of strongyloides hyperinfection syndrome, which occurs pre-
dominantly in infected adults who become immunosuppressed, whether by iatrogenic means
or otherwise [2].
It is increasingly acknowledged that S. stercoralis infection represents a significant public
health challenge and that action is required to deal with the problem [3], however there is no
general agreement as to what these measures should be. Some advocate the need for extensive
environmental management of the problem to interrupt transmission in endemic communi-
ties [4, 5]. They point out that pharmacological treatment can have side effects, cannot prevent
re-infection from environmental sources of the infection, and that resistance to ivermectin
may develop with excessive use. Others emphasize the efficacy and safety of treatment with
ivermectin, and advocate pharmacological control, with possible mass drug administrations
(MDA) in communities that have a high prevalence of infection in accordance with programs
currently employed to control other soil transmitted helminth and vector borne nematode
infections [1]. They point out that free-living forms of the parasite are relatively transient,
human beings constitute the major reservoir of infection, and while some resistance has been
noted in veterinary settings, to date there is no evidence of resistance in human infection. Still
others have advocated a combination of these approaches, employing case finding and treat-
ment with ivermectin, in association with public health measures such as improved sanitation
[6].
A measure of success has been reported to date, with studies employing both approaches
reporting positive results in control of the infection. [6, 7]
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It should be pointed out that the optimal measures for control of strongyloides infection
may differ from situation to situation, depending upon local factors such as rainfall and vegeta-
tion, the importance of agricultural practices in transmission, and the presence or otherwise of
adequate health infrastructure. Because of the chronic nature of this infection and its capacity
for sustained auto-infection within individuals, it is possible to have a high prevalence of infec-
tion both in communities where conditions allow for high transmission rates of the infection,
and equally in communities where transmission is lower, but there are a high number of
chronic, untreated infections.
The Aboriginal communities of northern Australia are home to some of the highest mea-
sured prevalence of this infection, with rates of 30–40% reported [8].
Oral ivermectin is now accepted as the treatment of choice for this condition, but disagree-
ment persists over the need for wide spread testing and elimination of the infection. Attention
has been drawn to some of the barriers preventing control of infection in these communities,
including difficulties with diagnosis and lack of adequate follow up of treated cases [9].
Direct parasitological diagnosis of infection and other coprological methods are generally
not feasible in these isolated communities, and are known to have a low sensitivity even when
performed under optimal conditions. ELISA testing is now generally accepted as being sensi-
tive and specific enough for use in both clinical and research settings [1, 10]. Concerns over
cross reactivity with other helminth infections have less relevance in the Australian setting
where these infections are not found. In practical terms in the Australian setting this equates
to testing using one of several commercially available ELISA tests. The reference ranges for
these tests were developed in relatively low prevalence populations and were intended to pre-
vent false positive results in situations where the infection is uncommon. For example, the
unreferenced product information for one such test (DRG laboratories) advises clinicians that
normal ranges may need to be interpreted “in the context of local settings”. Anecdotally, it is
reported that for this reason, clinicians working in communities where the infection is known
to be endemic frequently treat patients whose ELISA results fall under the published range, in
an attempt to avoid missing infections. To date there have been no attempts to validate this
approach, and studies of treatment efficacy have mostly been characterized by limited and
poor follow up of treated cases [8].
The current study comprises a three year follow up of a cohort of patients tested and treated
for strongyloides infection in an Aboriginal community in northern Australia as part of a
study into the relationship between S. stercoralis infection and type 2 diabetes mellitus [11]. It
is the first study to examine the long term outcome for adults tested and treated for the infec-
tion, who continue to live in an endemic community in the absence of any attempt at environ-
mental manipulation.
Furthermore, as the original cohort was established using a revised (and lower) cut off for
ELISA positivity, there can now be an attempt to validate the use of a lower ELISA threshold
for treatment by looking at response to treatment and long term outcomes in these patients.
Methods
Study population
The study was conducted in three aboriginal communities located within a 100 km radius of
each other in the far north Kimberley region of Western Australia. The communities are iso-
lated, with the nearest hospital and laboratory services being 800km away. Prior to the com-
mencement of this study, testing and treatment for S. stercoralis infection had not taken place
in any systematic manner.
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The cohort comprised 259 adult aboriginals attending the medical facilities in these com-
munities, and was originally established from April 2012 to December 2013 as part of a study
into the relationship between S. stercoralis infection and type 2 diabetes mellitus (T2DM). The
protocol for this study has been published previously [11].
Patients were offered testing and treatment for S. stercoralis infection on an opportunistic
basis when attending the clinics. No attempt was made to screen patients on the basis of pre-
senting symptoms, as it was felt that there was little evidence for the presence of reliable symp-
toms in chronic strongyloidiasis in an endemic setting. Recent results from a study conducted
in an Aboriginal community would seem to support this [12]. Patients who were normally res-
ident outside the communities were excluded, as were patients who had received prior treat-
ment with ivermectin, without serological testing for S. stercoralis.
Serological testing for S stercoralis
Diagnosis of S. stercoralis infection was established purely through serological means as direct
parasitological studies would have been logistically difficult in this setting, and would likely
have lacked sensitivity [13].
ELISA testing was carried out at a reference laboratory utilizing a commercial S. stercoralis
ELISA kit (DRG laboratories) that tests for the presence of IgG antibodies. All positive results
were subsequently tested in parallel and the revised value used in analysis.
The normal ranges (in units of absorbance) provided by the laboratory for this test were
: < 0.20 –Negative
: 0.20–0.40 –Equivocal
: > 0.40 –Positive
A prior survey in the study community had suggested that a prevalence of infection greater
than 30% was likely [14] and therefore, in order to reduce the possibility of false negative
results, a modified normal range was employed for diagnosis. All results greater than 0.30 were
considered as “positive”, and were treated. All results less than 0.30, including those less than
0.2, were considered “equivocal” from the point of view of follow up, and were placed on recall
for repeat testing in 6 months.
Treatment and follow up
All patients returning positive results according to the protocol were treated with 2 doses of
ivermectin 0.2mg/kg, given 2 weeks apart under direct observation.
All 259 patients in the study were then recalled after 6 months for repeat serological testing.
The results of 6 month testing have been published previously, as part of a study into the rela-
tionship of treatment outcomes and T2DM [15].
Any subjects found to be ELISA positive at 6 months were recalled for repeat treatment
with a single dose of ivermectin 0.2mg/kg. An audit of patient records shows that of the 29 sub-
jects who remained ELISA positive at 6 months, 24 received an extra dose of ivermectin at this
time, while 5 did not.
Routine follow up of patients was then conducted by the individual clinics. Clinic records
show that a further 5 subjects received a fourth dose of ivermectin, for presumed strongyloides
infection, during the subsequent 2½ years.
All subjects were finally recalled approximately 3 years after initial testing for repeat ELISA
testing and metabolic assessment. Any subjects found to be ELISA positive at this time were
treated with a further dose of ivermectin 0.2mg/kg. Three year follow up also involved an
assessment of the subject’s metabolic status as part of an ongoing study into the relationship
between strongyloides and T2DM, the results of which will be published separately [16].
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Treatment outcomes
Treatment outcome in this study was evaluated in two ways. Firstly, “treatment success” was
defined as a fall in ELISA serology to< 0.30 at follow up. “Treatment effect” was defined as a
ratio of post treatment ELISA to pre-treatment ELISA of less than 0.60.
As a modified normal range was used in this study to identify positive cases, at follow up it
was possible to compare two groups; those whose initial serology was above the established
positive range of 0.40 (designated “high titre”), and those whose initial serology was in the
range between 0.30 and< 0.40 (designated “low titre”) These groups were compared in
terms of treatment success and treatment effect on the basis that if those in the low titre group
represented true infections with S. stercoralis (rather than false positives) then treatment out-
comes should be similar to those achieved in the high titre group. Additionally outcomes for
the two groups were compared in terms of the average ELISA serology of both groups at 3
years follow up, on the basis that if both groups represented true infections, and both groups
were treated in the same way, then the two groups should be similar in terms of outcomes at 3
years.
Assessment of “non-responders”
During the course of follow-up it became apparent that a small number of subjects continued
to return positive ELISA results after three years of follow up, despite repeated treatment with
ivermectin (designated “non-responders”). Clearly it is of interest as to whether these non-
responders represent true treatment failure or re-infection, or whether they are simply con-
tinuing to produce a positive ELISA test in the absence of ongoing infection. To aid in the
assessment of these subjects, additional testing was carried out, including serological testing
for HTLV-1 virus, serum IgE, FBE, and a multivalent faecal PCR test for S. stercoralis targeting
a 101bp region of the 18S gene (Western Diagnostic Pathology, Myaree) [17]. Molecular test-
ing of faeces specimens was employed, as it is logistically easier to achieve from an isolated
location. Studies suggest that, although still less sensitive than serology, it has improved sensi-
tivity over direct parasitological methods[18].
Statistical analysis
McNemar’s chi-square test for correlated proportions was used to compare prevalence rates at
the different time points. Comparison of mean age and BMI and change in eosinophil count
between responders and non-responders was undertaken using independent samples t-tests.
No attempt was made to impute data for those lost to follow up. Logistic regression was used
to determine differences in outcome for high titre and low titre cases.
Ethics statement
The protocol for this study was approved by the Kimberley Aboriginal Health Planning
Forum. Ethical approval for the study was obtained through the Western Australian Aborigi-
nal Health Ethics Committee (WAAHEC) in 2014 (HREC Reference 515). All subjects
were over 18 years of age and provided informed verbal consent. Use of verbal consent was
approved by WAAHEC as no additional tests or treatments were required other than those
dictated by the current best management guidelines for this condition, and due to variable
rates of literacy in the study community. Consent was recorded electronically in the subject’s
permanent medical record.
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Results
Treatment outcomes
Demographic data for the 259 patients originally enrolled in the study are given in Table 1.
Successful follow up was achieved in 207 of the original cohort at 3 years, with 52 subjects
lost to follow up as outlined in Fig 1. Those lost to follow up were similar in terms of infection
status (36.5% vs. 35.2%, p = 0.85), with a tendency to be female (62% vs. 48%; p = 0.071). All
other baseline comparisons were similar.
Fig 2 gives a graphical illustration of the outcome in terms of serology for those followed up
at 6 months and 3 years. Treatment with ivermectin was highly effective, with the prevalence
of ELISA positive subjects falling from an initial 35.3% to 13.4% (McNemar’s chi2 = 46.6,
p<0.001) at 6 months and 5.8% (McNemar’s chi2 = 56.5, p<0.001) at 3 years, respectively.
Only three new cases were diagnosed in the first 6 months of follow up, with a further three
in the period up to 3 years. Three cases that had returned to negative at 6 months were found
to be ELISA positive again at 3 years. It should be noted that it is not possible to ascertain
whether these three cases represent relapse of existing infection, presumably through the pro-
cess of “auto-infection “which is known to occur in chronic strongyloidiasis, or re-infection
from environmental sources. The details of these subjects are summarized in Table 2.
All new cases at 6 months and 3 years involved only a marginal increase in ELISA, with
only two cases rising above the accepted positive range of 0.40, and the others deemed positive
due to the use of a reduced cut-off in this study. Additionally, the three cases that “relapsed”
after cure at 6 months in fact only dipped marginally below the cut-off of 0.30, before returning
to marginally above.
An analysis of treatment outcomes at 6 months with respect to treatment failure has been
published previously [15].
Non-responders
Of the 12 positive cases at 3 year follow up, 9 represent “treatment failure”, with these subjects
remaining ELISA positive throughout follow up, despite repeated treatment with ivermectin.
The details of these subjects are presented in Table 3 along with the results of the further tests
conducted. Comparisons of mean age, BMI and eosinophil counts with the subjects who
responded to treatment are included.
Analysis shows them to be significantly older (difference 11.7 years, 95% C.I. 1.6–21.8,
p = 0.024), and heavier (BMI difference 7.6, 95% C.I. 2.4–12.9, p = 0.005) than those who
responded to treatment, with a smaller fall in eosinophil count after treatment, which did not
Table 1. Demographic data.
Not treated Treated Overall Sig.
N % N % N % P
Age <30 18 10.7 17 18.7 35 13.5 0.141
30–39 64 38.1 26 28.6 90 34.8
40–49 44 26.2 20 22.0 64 24.7
50+ 42 25.0 28 30.8 70 27.0
Total 168 100.0 91 100.0 259 100.0
Sex Male 69 41.1 37 40.7 106 40.9 0.949
Female 99 58.9 54 59.3 153 59.1
Total 168 100.0 91 100.0 259 100.0
https://doi.org/10.1371/journal.pntd.0005825.t001
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Fig 1. Outcome of follow up at three years.
https://doi.org/10.1371/journal.pntd.0005825.g001
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reach statistical significance (difference -0.29, 95% CI -0.71–0.13, p = 0.167). Four of the seven
subjects tested had IgE levels in the normal range.
Comparison of outcomes for low titre and high titre cases
Table 4 shows a comparison of the outcomes for the low titre (initial serology 0.30 and<
0.40) and high titre (initial serology 0.40) groups.
As can be seen, the difference between the two groups in terms of treatment success is not
statistically significant, and they are very similar in terms of average ELISA titre at 3 year follow
up. There is a significant difference when compared in terms of “treatment effect”, but this not
significant when adjusted for initial ELISA titre.
Fig 2. Treatment outcome at three years. *One patient who tested positive to S.stercoralis but left the
community prior to treatment, has been excluded from analysis.
https://doi.org/10.1371/journal.pntd.0005825.g002
Table 2. New cases at follow up.
Subject Age Initial ELISA Six month ELISA Three year ELISA
Female 53 0.19 0.30^ 0.12*
Female 43 0.15 0.43^ 0.20*
Female 30 0.18 0.30^ 0.22*
Male 43 0.22 - 0.34^
Male 69 0.15 0.24 0.33^
Female 29 0.14 0.03 0.40^
Female 73 0.48^ 0.28 0.37^
Female 70 0.51^ 0.29 0.37^
Male 43 0.35^ 0.27 0.32^
*After treatment at 6 months follow up.
- Subject was lost to follow up at 6 months.
^Positive results.
https://doi.org/10.1371/journal.pntd.0005825.t002
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Discussion
The results of this study suggest that control [19] of Strongyloides stercoralis infection in this
adult Aboriginal population could be achieved by case finding and treatment alone. A marked
and sustained reduction in infection rates was seen in the study group without the need for
environmental manipulation, or repeated follow up and treatment beyond the current best
practice recommendations. The advantage with this strategy is that it requires no change in
the current diagnostic or treatment guidelines, simply a sustained clinical response from those
agencies providing health care in these communities.
The conditions present in Aboriginal communities differ in several ways from those in pop-
ulations elsewhere in the world, where different strategies for control of S. stercoralis have been
employed, and therefore the findings in this study may not be easily generalized.
Rates of S. stercoralis infection, as with other soil-transmitted helminths, are thought to rise
throughout childhood, peaking in late adolescence or early adulthood, and remaining rela-
tively constant through adult life [20]. In the study community it is likely that most infections
occur in childhood and adolescence as a result of recreational activities around watercourses.
Table 3. Details of non-responders.
Age Initial
BMI
Initial ELISA
(abs.)
Six month
ELISA
Final
ELISA
Initial eosin.
(x109)
Final eosin.
(x109)
HTLV-
1
IgE (kU/
ml)
Fecal
PCR
1 Male 75 30.37 0.65 0.45 0.45 0.59 0.13 Neg - * -
2 Female 58 32.94 0.67 0.59 0.4 0.37 0.23 Neg 323 -
3 Female 73 29.6 0.48 0.28 0.37 0.57 0.39 Neg 87 neg
4 Female 70 46.05 0.51 0.29 0.37 0.47 1.06 Neg - neg
5 Female 45 29.11 0.59 0.34 0.32 0.36 0.17 Pos 1010 -
6 Male 31 38.85 0.38 0.31 0.32 0.51 0.33 Neg 223 neg
7 Female 40 56.01 0.73 0.58 0.46 0.39 0.42 Neg 137 neg
8 Female 46 34.08 0.35 0.34 0.34 0.94 0.62 Neg 1187 neg
9 Male 43 24.4 0.35 0.27 0.32 0.85 0.62 Neg 214 neg
“Non-responders”
average
53.4 35.7 Av. Change In
eosin. 0.12
“Responders”
average
41.8 28.1 Av. change in
eosin. 0.41
Comparison Diff 11.7
p = 0.024
Diff 7.6
p = 0.005
Diff -0.29
p = 0.17
*Missing values are indicated by–
https://doi.org/10.1371/journal.pntd.0005825.t003
Table 4. Outcome for “low titre” subjects.
“Treatment success”
(% success)
“Treatment response”
(% effective)
Post treatment average ELISA
(95% C.I.)
“Low titre” ELISA
(N = 16)
13 (81.2) 10 (62.5) 0.146 (0.08–0.21)
“High titre” ELISA
(N = 58)
52 (89.7) 54 (93.1) 0.143 (0.11–0.17)
Analysis O.R. 2.0 (95% C.I 0.44–9.08,
p = 0.369
O.R. 8.1 (C.I. 1.9–34.0, p = 0.004)
Adjusted O.R.* 2.98(C.I. 0.46–19.31,
p = 0.25)
Difference = 0.003 (C.I. -0.07–0.06,
p = 0.92)
* Adjusted for initial ELISA titre
https://doi.org/10.1371/journal.pntd.0005825.t004
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A study conducted in Cambodia employed a strategy that involved both case finding and
treatment and attempts to improve sanitation, and reported success in control of infection
over a two year follow up [6]. The incident rate of new infection was higher in this setting
when compared to our study, and transmission was facilitated by agricultural practices that
are not a factor in Aboriginal communities. Furthermore, the standard of housing and hygiene
facilities in the Cambodian communities was lower and more variable.
It is not the case that improvements in hygiene were not necessary for control of STH infec-
tions in Aboriginal communities, rather that most of the necessary changes may have already
occurred over the past few decades. Studies of the prevalence of hookworm infection in north-
ern Australia suggest that control has been achieved through both pharmacological means
and improvements in housing [21, 22]. Current living conditions in Aboriginal communities
remain poor by broader standards, but in the current study community all individuals are, at a
minimum, housed in purpose built dwellings with toilet facilities.
Mass administration of ivermectin has been advocated for control of S. stercoralis in high
prevalence communities. This strategy appears to have been effective in Central American
studies examining the administration of ivermectin for control of onchocerciasis, with sus-
tained falls in the prevalence of S. stercoralis infection in areas subject to regular MDA com-
pared to those who are not [7].
Such MDA programs would potentially have secondary health benefits in Aboriginal com-
munities in terms of a reduction in Sarcoptes scabiei infections, with a subsequent reduction in
Group A streptococcal infection and its sequelae of rheumatic fever and post-streptococcal
glomerulonephritis. Trials of this approach have been conducted in Northern Australia with
variable results [3]. The results of two MDA’s of ivermectin for the treatment of strongyloides
in an Australian Aboriginal community have recently been published in this journal. A
marked reduction in the prevalence of strongyloides at 6 and 18 months was demonstrated
using this approach [12]. Such a strategy however, would require the active participation of
affected communities and public health authorities alike, and agreement on the need for such
a program has not yet been reached [23].
Clinical effects of treatment
The principal aim of this study was to determine the effectiveness of a “case finding and treat-
ment” approach to controlling S. stercoralis infection in an Aboriginal community. No attempt
was made in our study to characterize the initial symptoms of subjects with chronic strongyloi-
diasis, and therefore there are no data with regard to improvements in the well-being or health
of the community in response to treatment. A recent, much larger trial published in this jour-
nal did examine the benefits in terms of symptom control of MDA for strongyloides, and
found no evidence of a significant change in symptom profile [12]. Most discussion of the ben-
efits of controlling strongyloides infection has centred on the prevention of hyperinfection in
immunocompromised individuals, and such patients are routinely treated on a purely empiri-
cal basis in parts of northern Australia [12]. No cases of hyperinfection were recorded in the
study community during the course of the study.
Our prior study identified T2DM as a risk factor for failure for treatment of S. stercoralis
[15]. No meaningful association of T2DM with treatment outcome could be identified at 3
years because of the very low number (9 subjects, 3 of whom had T2DM) failing to serocon-
vert. Extensive data however have been recorded in regard to the metabolic outcome for the
subjects in this study and these will be reported on separately [16]. In summary, the data
showed a differential effect of treatment for S. stercoralis on the metabolic outcomes for
patients depending on their diabetic status. The incidence of worsening glucose metabolism in
Follow up of Strongyloides stercoralis treatment
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non-diabetic patients (new cases of T2DM or glucose intolerance) was higher in the treatment
group (RR 3.75, CI 1.06–13.2, p = 0.04). At the same time improving diabetic control as mea-
sured by HbA1c was noted in the treated diabetic group (Diff = -1.03, p = 0.009). While the
low numbers in this trial mean that this result should be interpreted cautiously, they are in
agreement with another recently published study into the effect of albendazole treatment for
STH infection on subsequent insulin resistance [24]. The possible adverse effect of treatment
on glucose metabolism is of importance when considering the case for MDA in strongyloides.
As a public health measure, MDA does not allow for consideration of the individual clinical
state of the subjects being treated, and therefore intervention to monitor and improve the glu-
cose metabolism of individuals at risk of developing T2DM is not possible.
Limitations of the present study include its reliance on serological means alone for diagnos-
ing S. stercoralis infection, as direct parasitological tests are required to ensure maximum spec-
ificity. However, as already noted, direct methods lack sensitivity, are difficult to employ in
remote locations, and can over estimate the response to treatment [10].
Several caveats need to be raised on the effectiveness and feasibility of a case finding and
treatment strategy. Firstly, the current study deals only with an adult population, and little or
nothing is known of the situation with respect to the prevalence of infection, and effectiveness
of treatment in the paediatric population. Logically it would seem likely that infection and re-
infection rates might be higher in children, where hygiene practices may be less rigorous and
activities where infection could occur more common. Disagreement on the need for elimina-
tion in adults still exists, and this may be even more so in the case of children. Few clear severe
adverse health effects of chronic infection have been demonstrated in children, and the major
health consequence in adults- the occurrence of strongyloides hyperinfection syndrome in
immunosuppressed patients-has been reported only rarely in children [2, 25]. It may therefore
be reasonable to employ a regimen where cohorts of children are screened and treated as part
of health screening procedures as they reach adulthood. Furthermore, as noted above, there is
increasing evidence that pre-existing helminth infections may have beneficial effects on meta-
bolic parameters in later life, and this potential effect may need to be taken into consideration
when considering treatment in populations where type 2 diabetes mellitus is extremely preva-
lent [26].
Case finding and treatment also relies on the accurate and sensitive diagnosis of infection
by the means currently available, as large numbers of false negative tests would be a problem
for effective control. The similarity in response to treatment between the “low” and “high “titre
groups in this study suggests that it may be appropriate to treat individuals whose ELISA val-
ues fall just below the positive range when working in a high prevalence community. Further
research into the appropriate ELISA normal range for these populations may be of benefit.
Accurate follow up of treated cases would also be important in a case finding and treatment
strategy. A significant number (9 cases, 9.8%) in this study remained ELISA positive through-
out the study period despite adequate treatment, and it is important to know whether these
represent true infections. Repeated re-infection of these subjects would seem unlikely as an
explanation given the low overall incident rate of infection in the population. Resistance of the
worm to treatment is certainly a possibility, although this is yet to be reported in a human pop-
ulation [4]. Alternately, it is possible that a persistent antibody response has developed in these
individuals in the absence of ongoing infection, in a situation analogous to the “serofast”
response sometimes seen in treponemal infection [27]. Further investigation of the 9 subjects
in this study has not served to settle the matter. Faecal PCR studies were conducted in 6 cases
and were negative, suggesting an absence of infection, or at least an absence of larval shedding
at the time of testing. Eosinophilia is known to be an unreliable indicator of infection [28],
however it is perhaps of note that eosinophilia rates that differed prior to treatment in the
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responding and non-responding subjects were almost identical following treatment. HTLV-1
infection is known to pre-dispose to severe and persistent strongyloides infection [29], but was
present here in only one individual. IgE levels are commonly elevated in chronic infection but
are reported to be normal in some cases, particularly in those co-infected with HTLV-1 and in
the elderly [30]. Only two of the patients in this group had elevated levels of IgE at follow up.
On balance, the further tests conducted on the 9 non-responder cases in this study do not sup-
port the presence of on-going infection with S. stercoralis. Clearly further studies to character-
ize the immune response in subjects such as these would be of interest, as it is known that
changes in relative levels of inflammatory and anti-inflammatory cytokines occur in patients
following successful treatment for S. stercoralis infection [31].
It should be noted that if the 9 non-responder subjects are excluded from analysis on the
presumption that they are no longer infected, then the prevalence of S. stercoralis in this cohort
3 years after treatment falls to just 1.4%, underlining once again the success of this treatment
strategy.
Conclusion
In conclusion, this study provides evidence that control of chronic S. stercoralis infection in an
adult Aboriginal population may achieved through a process of case finding and treatment,
using the current best practice guidelines for treatment. This strategy could be employed as an
alternative to mass drug administration, and does not rest upon the need for environmental
manipulation.
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